Canndoc, a subsidiary of InterCure, funds the most comprehensive study to date at Shamir Medical Center in Israel
Israeli medical cannabis company InterCure announced yesterday that its subsidiary Canndoc has signed an agreement with the Shamir Medical Center for a clinical research program on children with autism. The program will be led by Dr. Orit Stoller, pediatric neurologist at the Autism Center of the Shamir Medical Center, and Professor Mati Berkovitch, head of the hospital's clinical pharmacology unit.
InterCure's share price jumped by 5%, with a market capitalization of 499 million shekels. The company is headed by Alex Rabinovitch, and former Israeli Prime Minister Ehud Barak, as well as Alon Granot, former CFO of Frutarom, who heads Canndoc.
This research program, with a duration of 24 months, will be conducted with 100 patients, making it one of the longest studies conducted to date. Canndoc will finance the entire cost of the study. The oils produced by Canndoc are manufactured according to the EU GMP standards, which means that the company controls the composition of many of the substances that make up them, not just CBD and THC as required by Israeli regulations. Interchangeable products that are identical, or at least similar, from batch to batch, form the basis for meaningful clinical trials of cannabis-based treatments.
Canndoc already supplies cannabis-based products to children with autism spectrum disorders and has even been offering these products at subsidized prices since the introduction of the new medical cannabis regulatory framework, which has raised prices. The company claims that over the years, it has provided more 500 000 products to more than 15 000 patients, including children with autism spectrum disorders.
Other clinical trial programs planned
Canndoc is planning further clinical trials to test the effect of cannabis on epilepsy, fibromyalgia, neuropathic pain, side effects of chemotherapy, Parkinson's disease, arthritis, post-traumatic stress disorder and other pathologies.
"The incidence of diagnosis of children with autism spectrum disorders is rising and now stands at one child on 59, according to US statistics," said Dr. Stoller. "Conventional drug treatment currently provides a partial answer. In recent years, cannabis use in this population has been steadily increasing, and medical marijuana appears to respond well to some of the symptoms associated with autism spectrum disorders.
"This study is the first of its kind. It aims to test the effect of medical cannabis treatment on cognitive functionality, functions and symptoms such as sleep, diet, agitation, violence and anxiety. This information is vital to establish the legitimacy of medical cannabis treatment, and the treatment method, as part of the range of treatments offered to autistic children. "